Peptide Stack Analyzer Tool Peptide Directory Peptide Discussion Forum Peptide Tools: Stacker & Calculators Trusted Vendors + Vendor Red Flags
Labels

AICAR Dosage & Reconstitution Guide (AMPK Fat Loss Peptide Explained)

AICAR

AICAR (5-aminoimidazole-4-carboxamide riboside), also known as acadesine or AICA-riboside, is a metabolic research compound studied for its effects on cellular energy signaling, adenosine regulation, and AMP-activated protein kinase (AMPK). It is not a peptide.

How It Works

AICAR → Cellular Uptake → ZMP Formation → AMPK-Related + Adenosine-Regulating Effects

After entering cells, AICAR can be phosphorylated to AICAR monophosphate (ZMP), which can influence AMPK-related metabolic signaling. AICAR/acadesine has also been studied as an adenosine-regulating agent. Research has investigated effects on glucose metabolism, fatty-acid metabolism, ischemia, and cellular energy regulation.

Important Distinction

AICAR is not a peptide; it is a purine nucleoside-related metabolic research compound.
Human clinical research exists, but published studies have primarily used intravenous administration rather than modern subcutaneous research-use protocols.
Much of the endurance and exercise-mimetic discussion comes from preclinical research and should not be treated as an established human performance effect.
AICAR is not an approved fat-loss, endurance, or body-composition therapy.
AICAR Research-Use Protocol
Important Evidence Distinction:
The protocol below reflects dosing ranges and subcutaneous use commonly discussed in research-use and peptide communities. It is not an established human clinical AICAR protocol. Published human AICAR/acadesine studies have generally used very different doses, routes, and treatment settings, including intravenous administration.
50 mg Vial + 3.0 mL BAC Water → 1 Unit ≈ 166.7 mcg → Gradual Research-Use Framework
Standard Setup
Vial 50 mg
Water 3.0 mL bacteriostatic water
Concentration 16.67 mg/mL
Conversion 1 unit ≈ 166.7 mcg
Weeks 1–2
Starting Research-Use Range
Daily Dose 1,000 mcg (1 mg)
Units ≈ 6 units
Volume ≈ 0.06 mL
Weeks 3–4
Build Phase
Daily Dose 2,000 mcg (2 mg)
Units ≈ 12 units
Volume ≈ 0.12 mL
Weeks 5–8
Higher Research-Use Range
Daily Dose 3,000 mcg (3 mg)
Units ≈ 18 units
Volume ≈ 0.18 mL
Research-Use Schedule
Frequency Once daily
Commonly Discussed Timing Morning or pre-workout
Research-Use Route Subcutaneous
Commonly Discussed Cycle 4–8 weeks
Why use a gradual build?
The gradual 1 mg → 2 mg → 3 mg progression is a research-use framework intended to make response and tolerability easier to track. It should not be interpreted as a dose-escalation schedule established through controlled human clinical trials.
Clinical Research Comparison:
Human AICAR/acadesine studies have used substantially different exposures and have primarily investigated intravenous administration in metabolic, pharmacologic, and cardiovascular settings. Those clinical doses cannot be directly converted into equivalent subcutaneous doses.
What the Human Research Actually Shows
Human Clinical Evidence
AICAR/acadesine has been administered to humans in controlled clinical research.
Early pharmacokinetic research evaluated oral and intravenous doses ranging from 10–100 mg/kg in healthy volunteers.
AICAR has also been studied intravenously in metabolic research involving glucose and fatty-acid metabolism.
Large clinical programs investigated intravenous acadesine during coronary artery bypass surgery.
The large RED-CABG randomized trial did not demonstrate a reduction in its primary composite cardiovascular outcome.
Human clinical research does not establish AICAR as a fat-loss, endurance-enhancing, or exercise-replacement treatment.
Important:
Evidence that AICAR affects metabolic pathways does not automatically mean that it produces clinically meaningful fat loss or improved athletic endurance in humans.
Route & Administration Context
Clinical vs Research-Use Routes
Published Human Research Primarily intravenous
Oral Research Studied, but oral bioavailability was reported as very low
Subcutaneous Use Not established as a standard clinical route
Best Time of Day No clinically established timing
Route matters:
Human data from intravenous acadesine cannot simply be converted into an equivalent subcutaneous dose. Route changes absorption, exposure, pharmacokinetics, and potentially safety.
Real-World vs Clinical Use
Research-Use Discussions
Common Context Metabolic, endurance, and body-composition research
Evidence Limitation Modern SC protocols are not clinically validated
Published Human Research
Route Primarily IV
Research Areas Cardiac ischemia, pharmacokinetics, and metabolism
Performance Protocol Not established
Simple takeaway:
AICAR has legitimate human research, but that research should not be used to validate the low-dose subcutaneous endurance and fat-loss protocols commonly circulated online.
Concentration & Mathematical Dose Conversion (50 mg Vial)
Important:
The information below shows concentration math only. It does not establish that any listed amount is an appropriate or clinically validated AICAR dose.
Example Concentration
Vial 50 mg
Liquid Volume 3.0 mL
Concentration 16.67 mg/mL
U-100 Conversion 1 unit ≈ 166.7 mcg
Mathematical Reference
6 units ≈ 1 mg
12 units ≈ 2 mg
18 units ≈ 3 mg
30 units ≈ 5 mg
60 units ≈ 10 mg
Evidence distinction:
Correct concentration math does not validate the underlying dose. The 1–10 mg amounts above are mathematical examples only and should not be interpreted as doses established through human AICAR clinical trials.
Storage & Stability
Storage Considerations
Follow the storage specifications supplied for the specific research material or manufactured preparation.
Do not assume that generic peptide storage rules apply to AICAR because AICAR is not a peptide.
Stability after preparation depends on formulation, solvent, sterility, concentration, temperature, and manufacturer data.
A universal “4 weeks after mixing” shelf life is not established by the human clinical literature.
Cycle Length & Time Between Cycles
4–8 Week Research-Use Cycle → 2–4 Week Break → Reassess
Commonly Discussed Research-Use Framework
Cycle Length 4–8 weeks
Time Off 2–4 weeks
Use Style Defined metabolic or endurance-focused research phase
Evidence distinction:
The 4–8 week cycle with a 2–4 week break is commonly discussed in research-use settings, but it has not been established through controlled human clinical trials as a standard AICAR cycle or required washout period. Published human AICAR/acadesine studies used study-specific exposures, primarily through intravenous administration.
Ways the Research-Use Framework Is Structured
Shorter Framework 4 weeks on, 2 weeks off
Commonly discussed for a shorter defined metabolic or performance-focused research period.
Longer Framework 8 weeks on, 4 weeks off
Represents the longer end of commonly discussed research-use cycles.
Training-Block Approach Defined research period only
Use is sometimes discussed around a specific endurance or metabolic research phase rather than continuous exposure.
When to Reassess or Stop Sooner
Unexpected fatigue or low-energy symptoms develop
Symptoms consistent with altered glucose regulation occur
Training performance or recovery worsens rather than improves
Unexpected cardiovascular or systemic symptoms occur
Important:
Research-use cycle information should not be confused with clinical dosing. Long-term repeated subcutaneous AICAR use has not been adequately characterized in controlled human studies.
Monitoring During Research
Blood pressure and heart rate
Glucose and metabolic response when relevant to the research setting
Uric acid, which has increased during higher-dose human acadesine research
Overall cardiovascular and systemic tolerability
Research Findings & Potential Effects
Activates or influences AMPK-related cellular energy signaling
Human metabolic research has investigated effects on glucose and fatty-acid metabolism
Human research has also investigated adenosine regulation and myocardial ischemia
Preclinical studies have investigated endurance and exercise-related metabolic effects
Evidence note:
The endurance and “exercise mimetic” reputation of AICAR comes largely from preclinical research. Controlled human evidence does not establish AICAR as an endurance-enhancing or fat-loss treatment.
Potential Side Effects & Safety Considerations
Changes in cardiovascular physiology can occur; human IV research has reported increased heart rate and decreased blood pressure under some experimental conditions.
Higher-dose acadesine research has reported increases in plasma uric acid.
Effects on glucose and fatty-acid metabolism may be relevant when interpreting metabolic symptoms or laboratory results.
Safety of repeated low-dose subcutaneous use has not been adequately established in controlled human trials.
Important Notes
AICAR is a metabolic research compound, not a peptide.
Human clinical research exists, but it does not validate commonly circulated 1–3 mg daily SC protocols.
Published human research has primarily involved IV administration and substantially different exposures.
Clinical IV doses should not be converted directly into self-administered SC doses.
AMPK activation does not by itself prove meaningful fat loss or endurance enhancement in humans.
No validated 4–8 week performance cycle or required 2–4 week washout period has been established.
Bottom line:
AICAR has legitimate human pharmacology and clinical research, but the evidence base is very different from the modern subcutaneous fitness protocols commonly circulated online. Those two bodies of information should remain clearly separated.

Important Disclaimer

AICAR is not FDA-approved for human use and is classified as a research compound. This content is for educational purposes only.

Research & References

Primary Research

View AICAR Guide → Peptide Directory →
Email Post
Similar Links:

Comments

Post a Comment